Endocrine And Glucose Metabolic Effects Of Compound Cyproterone Acetate In Women With Polycystic Ovary Syndrome

Objective: To investigate the clinical efficacy and safety of compound cyproterone acetate(CPA) in the treatment of polycysticovary syndrome (PCOS) and to study endocrine and glucose metabolic effects of compound cyproterone acetate(CPA) in women with polycystic ovary syndrome. Methods: Thirty-five proven PCOS patients were enrolled. They received compound cyproterone acetate(CPA) for 3 cycles. Serum sexhormone, fasting glucose, fasting insulin and transvaginal pelvic ultrasonography were determined before, 3 cycles after treatment. Results: 34 patients had regular uterine bleeding during CPA Co therapy and 2 pregnancies achieved. Hirsute and acne score decreased significantly (P<0.01). Serum E₂, LH, FSH, LH/FSH decreased significantly(P<0.01). Testosterone(T) decreased from 1.28±0.70 to 0.80±0.41(P<0.01), dehydroepiandrosterone sulfate (DHEAS) from 9.80±5.46 to 4.19±3.08(P<0.01), and free androgen index(FAI) decreased from 4.62±2.97 to 0.98±0.74(P<0.01), while SHBG levels increased from 55.51±28.79 to 102.95±50.67(P<0.01). Fasting glucose remained unchanged (P>0.05). Fasting insulin concentrations and insulin resistance decreased significantly(P<0.01). Insulin sensitivity index (ISI) did not change significantly(P>0.05). Bilateral ovarian volumes shrunk and follicle numbers decreased significantly (P<0.05～0.01). Conclusion: CPA Co has antiandrogenic effects on PCOS patients and improve their edocrine. It decreased fasting insulin and improve insulin resistance, without changing fasting glucose and insulin sensitivity. The long-term glucose metabolic effects of CPA Co on women with PCOS require further investigations.